Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
42 patients were aged < 65, ≥ 65 to < 75, and ≥ 75 years, respectively.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
These findings support PAL + ET as a viable treatment option for all patients, including the elderly, while highlighting the need for close monitoring and individualized treatment strategies, especially in older patients. [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s12282-025-01812-5.
[BACKGROUND] Palbociclib (PAL), a cyclin-dependent kinase 4/6 inhibitor, plus endocrine therapy (ET) is recommended as first-line (1L) treatment for hormone receptor-positive (HR+)/ human epidermal gr
APA
Masuda H, Nagai SE, et al. (2026). Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group.. Breast cancer (Tokyo, Japan), 33(2), 333-345. https://doi.org/10.1007/s12282-025-01812-5
MLA
Masuda H, et al.. "Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group.." Breast cancer (Tokyo, Japan), vol. 33, no. 2, 2026, pp. 333-345.
PMID
41670927
Abstract
[BACKGROUND] Palbociclib (PAL), a cyclin-dependent kinase 4/6 inhibitor, plus endocrine therapy (ET) is recommended as first-line (1L) treatment for hormone receptor-positive (HR+)/ human epidermal growth factor 2 negative (HER2-) advanced breast cancer (ABC). Despite broad use in real-world clinical settings, few studies have evaluated its effectiveness in elderly patients in Japan.
[METHODS] The multicenter, observational P-BRIDGE study included HR+/HER2- ABC patients ( = 693) who initiated PAL + ET as 1L or second-line treatment during 2017–2020 in Japan. Treatment outcomes and patterns were evaluated by age category (< 65; ≥ 65 to < 75; ≥ 75 years).
[RESULTS] Among patients treated with 1L PAL + ET ( = 426), 266, 118, and 42 patients were aged < 65, ≥ 65 to < 75, and ≥ 75 years, respectively. Patients aged ≥ 75 years were less likely to initiate PAL at 125 mg (64.3%) than patients aged < 65 (95.5%) and ≥ 65 to < 75 (88.1%) years. More patients aged ≥ 75 years discontinued PAL due to adverse events than other age groups. Median real-world progression-free survival (95% CI) was 24.5 months (18.2–30,4), 25.7 months (16.8–36.7), and 45.4 months (20.4–52.4), in the < 65, ≥ 65 to < 75, and ≥ 75-year age groups, respectively. Corresponding median overall survival was 68.2 months (65.0-not reached [NR]), NR (56.3-NR), and 68.0 months (45.8-NR), respectively.
[CONCLUSIONS] The effectiveness of PAL + ET in elderly patients in the real-world setting in Japan appears comparable to other age groups. These findings support PAL + ET as a viable treatment option for all patients, including the elderly, while highlighting the need for close monitoring and individualized treatment strategies, especially in older patients.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s12282-025-01812-5.
[METHODS] The multicenter, observational P-BRIDGE study included HR+/HER2- ABC patients ( = 693) who initiated PAL + ET as 1L or second-line treatment during 2017–2020 in Japan. Treatment outcomes and patterns were evaluated by age category (< 65; ≥ 65 to < 75; ≥ 75 years).
[RESULTS] Among patients treated with 1L PAL + ET ( = 426), 266, 118, and 42 patients were aged < 65, ≥ 65 to < 75, and ≥ 75 years, respectively. Patients aged ≥ 75 years were less likely to initiate PAL at 125 mg (64.3%) than patients aged < 65 (95.5%) and ≥ 65 to < 75 (88.1%) years. More patients aged ≥ 75 years discontinued PAL due to adverse events than other age groups. Median real-world progression-free survival (95% CI) was 24.5 months (18.2–30,4), 25.7 months (16.8–36.7), and 45.4 months (20.4–52.4), in the < 65, ≥ 65 to < 75, and ≥ 75-year age groups, respectively. Corresponding median overall survival was 68.2 months (65.0-not reached [NR]), NR (56.3-NR), and 68.0 months (45.8-NR), respectively.
[CONCLUSIONS] The effectiveness of PAL + ET in elderly patients in the real-world setting in Japan appears comparable to other age groups. These findings support PAL + ET as a viable treatment option for all patients, including the elderly, while highlighting the need for close monitoring and individualized treatment strategies, especially in older patients.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s12282-025-01812-5.